Screener
Perspective Therapeutics CATX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -39.5%-8.2pp | -35.2%-2.1pp | -41.4%+1.9pp | -37.1%-7.2pp | -31.3%-5.1pp | |
| Return on invested capital | -48.2%+17.5pp | -44.3%+15.3pp | -55%+5.2pp | -73.1%-12.5pp | -65.7%-10.3pp | |
| Liquidity | ||||||
| Current ratio | 6.6×-8.5× | 8.7×-8.3× | 5.2×-7.5× | 8.7×-0.9× | 15.1×-12.6× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.68-25.0% | $3.35-14.8% | $2.80-37.8% | $3.26-29.9% | $3.58-30.0% | |
| Valuation | ||||||
| Market capitalization | $342.14M+25.3% | $475.1M+201% | $204.43M-5.2% | $254.72M-71.7% | $283.55M-57.8% | |
| Price / book | 1.1×0.0× | 1.4×+0.8× | 1×+0.2× | 1.1×-1.7× | 1.1×-0.9× |
FAQ
- What are Perspective Therapeutics's profit margins?
- Perspective Therapeutics (CATX) runs a 33.1% gross margin and a -292.7% operating margin, with a -218.4% net margin.
- Where do Perspective Therapeutics's ratios come from?
- Every ratio is computed from Perspective Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.